Materna Medical

Materna Medical operates within the OBGYN MedTech space, a market it estimates to be valued at approximately $25 billion, by developing technologies to address unmet needs in women's pelvic healthcare. The company's business model involves the development and commercialization of medical devices sold directly to consumers and through healthcare professionals. To date, Materna has raised $57.7 million in funding over nine rounds, with the latest being a Series B2 round in May 2024 for $20 million, led by InnovaHealth Partners.

The company has two primary products. The first, Milli™, is an all-in-one, patient-controlled vaginal dilator designed to address conditions like vaginismus and painful sex. Launched as a wellness device in 2019, Milli gained FDA clearance for over-the-counter sales in 2023, enhancing accessibility for patients. The device is unique in its ability to expand incrementally by millimeters and includes a vibration feature. The second product, the Ellora™ System (formerly Materna Prep), is an investigational device aimed at reducing pelvic floor muscle injuries during vaginal childbirth. This system is designed to prepare the pelvic floor muscles through slow, incremental stretching during labor. It is currently undergoing a large randomized controlled trial, the EASE trial, across 20 U.S. hospitals, with plans for an FDA De Novo submission.